Sickle Cell in Focus 2021
1.
The course met the stated objectives:
A. Create awareness of common medical emergencies in the older adult with sickle cell disease to educate healthcare professionals on treatment options available to SCD patients who present these common complications
B. Acquire a greater understanding of new technologies and their potential implications in the advancement of treatment and increased disease knowledge of sickle cell disease
C. Become aware of recent FDA-approved drugs and how to utilize them in the context of standard of care hydroxyurea therapy. Become aware of existing curative therapies, genetic and genomic therapies under clinical development, and which patients could be considered for such therapies.
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
2.
As a result of my participation in this activity, I will commit to:
3.
Rate the quality of the faculty member(s), from 5 (Excellent) to 1 (Poor) taking into consideration their content, clinical relevance, teaching strategies, and level of expertise.
5 (Excellent)
4
3 (Moderate)
2
1 (Poor)
4.
Will you change the way you practice based on this activity?
Yes
No
5.
Do you feel the activity was balanced, objective and free from commercial bias?
Yes
No
6.
Approximately what percent of this content was NEW to you?
25%
50%
75%
This was all new information to me.
7.
What I liked about this activity...?
It increased my knowledge
It will improve communication with the healthcare team
It provided information in ways that I can review again later
It gave me the opportunity to apply information to realistic scenarios that I confront in my practice
It facilitated applying values/ethics to interprofessional practice
8.
What was the most useful information you gained from this activity?
9.
Suggested topics for future Sickle Cell in Focus Conferences
10.
General comments/suggestions
Current Progress,
0 of 10 answered